Form 4: Charles River Laboratories Director Nancy Andrews Acquires Equity Through RSU and Option Grants

Nancy C. Andrews, a Director at Charles River Laboratories International, Inc., has acquired 946 shares of common stock as restricted stock units and 2,076 stock options, aligning her interests with shareholders.

Summary

• Nancy C. Andrews, a Director of Charles River Laboratories International, Inc. (CRL), acquired 946 shares of common stock in the form of restricted stock units (RSUs) on May 21, 2025.
• These RSUs were acquired at a price of $134.98 per share.
• Following this transaction, Ms. Andrews beneficially owns 3,964 shares of common stock.
• The unvested RSUs are set to vest upon the earlier of May 21, 2026, or the business day prior to the Company's next annual meeting of shareholders.
• Additionally, Ms. Andrews acquired 2,076 stock options (right to buy) on May 21, 2025, with an exercise price of $134.98 per share.
• These stock options become exercisable upon the earlier of May 21, 2026, or the business day prior to the Company's next annual meeting of shareholders, and have an expiration date of May 21, 2035.
• After this transaction, Ms. Andrews beneficially owns 2,076 stock options.
• The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as it indicates a director's increased equity stake, aligning their interests with shareholders. This is a routine compensation event and not indicative of significant operational or financial changes, hence not extremely positive.

Positives

• The acquisition of additional equity by a director, even if compensation-related, generally indicates alignment of management's interests with those of shareholders.
• The use of Rule 10b5-1(c) plans demonstrates a pre-planned and transparent approach to insider equity transactions.

Future Outlook

The acquired restricted stock units and stock options are scheduled to vest and become exercisable, respectively, upon the earlier of May 21, 2026, or the business day prior to the Company's next annual meeting of shareholders, indicating future equity ownership and potential exercise.

Industry Context

This Form 4 filing is a routine disclosure of an insider equity transaction, common across all industries, particularly for publicly traded companies that use equity compensation to align director and executive interests with shareholders. It does not provide specific insights into broader industry trends for the contract research organization (CRO) or life sciences sector in which Charles River Laboratories operates.

Stakeholder Impact

• Shareholders: The acquisition of equity by a director can be viewed positively as it aligns the director's financial interests with the long-term performance of the company, potentially encouraging decisions that enhance shareholder value.

Next Steps

• Vesting of 946 restricted stock units upon the earlier of May 21, 2026, or the business day prior to the Company's next annual meeting of shareholders.
• Exercisability of 2,076 stock options upon the earlier of May 21, 2026, or the business day prior to the Company's next annual meeting of shareholders.

Key Dates

Keywords

Charles River Laboratories, CRL, SEC Form 4, Insider Transaction, Restricted Stock Units, Stock Options, Equity Compensation, Director, Corporate Governance